Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
9vHPV Vaccine 2-dose Regimen in Children 4-8 Years Old
NCT05329961Phase 1Active, not recruiting
- Sponsor
- Boston Medical Center
- Start
- Sep 2022
- Primary completion
- Jul 2028
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection, sponsored by Boston Medical Center. Primary endpoint: Geometric Mean Titers (GMT) for HPV Antibodies at 60 months. Started Sep 2022; status: active, not recruiting.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT05329961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05329961.